Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pill vs. needle: can Lower-Dose blood thinners protect blood cancer patients from deadly clots?

NCT ID NCT07270263

Disease control Sponsor: Medical University of Gdansk Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of blood thinners taken as pills (apixaban and rivaroxaban) against a standard daily injection (enoxaparin) to prevent dangerous blood clots in people with blood cancers like lymphoma, leukemia, and multiple myeloma. About 100 participants will be randomly assigned to one of the three treatments for at least six months. The goal is to see which option is safest and most effective at preventing clots while minimizing bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
apixaban, rivaroxaban, and enoxaparin (low-molecular-weight heparin)
What this could lead to
If successful, this could offer blood cancer patients a safer, more convenient pill option to prevent blood clots, reducing the need for daily injections.
What could go wrong
This is a small, early-phase study with only 100 participants, so results may not apply to all patients. There is a risk of bleeding with any blood thinner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or high risk of venous thromboembolism, VTE) * Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin (LMWH) (enoxaparin 40 mg subcutaneously once daily). Exclusion Criteria: * Major bleeding within the last month (including gastrointestinal or intracranial bleeding). * Active major bleeding. * Hemoglobin concentration \< 8 g/dL. * Thrombocytopenia with platelet count \<30 × 10⁹/L. * ECOG performance status of 3 or 4. * Expected survival \<6 months. * History of mechanical heart valve or severe mitral stenosis. * Estimated glomerular filtration rate (eGFR) \< 25 mL/min. * Hepatic impairment (ALT ≥ 3× upper limit of normal or bilirubin ≥ 2× upper limit of normal). * Acute coronary syndrome or ischemic stroke within the last 6 months. * Anticipated significant drug-drug interactions between DOACs and anticancer agents. * Known antiphospholipid syndrome (APS).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignacies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm leukemia lymphoma myeloproliferative neoplasm plasma cell myeloma pulmonary embolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignacies Leukemia Lymphoma Multiple myeloma (MM), lymphoma, large B-cell, diffuse (DLBCL), lymphoma Pe - pulmonary embolism Venous thromboembolic disease Vte (venous thromboembolism)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Haematology & Transplantology

    RECRUITING

    Gdansk, Pomeranian Voivodeship, 80-152, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.